Corvus Pharmaceuticals (NASDAQ:CRVS) was given a new $30.00 price target on by analysts at Mizuho.
Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know [Yahoo! Finance]
Corvus Pharmaceuticals (CRVS) Soars 212% on Impressive Eczema Therapy Study [Yahoo! Finance]
Why Corvus Pharmaceuticals (CRVS) Is Up 211.8% After Upsized Equity Raise On Soquelitinib Phase 2 Plans [Yahoo! Finance]
Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M